Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-546b4f848f-hhr79 Total loading time: 0 Render date: 2023-06-05T01:13:55.368Z Has data issue: false Feature Flags: { "useRatesEcommerce": true } hasContentIssue false

Section VII - Pharmacotherapy for Dystonia

Published online by Cambridge University Press:  31 May 2018

Edited by
Dirk Dressler ,
Eckart Altenmüller  and
Joachim K. Krauss
Dirk Dressler
Affiliation:
Hannover Medical School
Eckart Altenmüller
Affiliation:
Hochschule für Musik, Theater und Medien, Hannover
Joachim K. Krauss
Affiliation:
Hannover Medical School
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Treatment of Dystonia , pp. 261 - 296
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Albanese, A, Asmus, F, Bhatia, KP, Elia, AE, Elibol, B, Filippini, G, Gasser, T, Krauss, JK, Nardocci, N, Newton, A, Valls-Solé, J (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18: 5–18.CrossRefGoogle ScholarPubMed
Balash, Y, Giladi, N (2004) Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 11: 361–370.CrossRefGoogle ScholarPubMed
Burke, RE, Fahn, S, Marsden, C (1986) Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36: 160–164.CrossRefGoogle ScholarPubMed
Chen, JJ, Ondo, WG, Dashtipour, K, Swope, DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Therapeutics 7: 1487–1504.CrossRefGoogle Scholar
Cloud, LJ, Jinnah, HA (2010) Treatment strategies for dystonia. Expert Opin Pharmacotherap 11: 5–15.CrossRefGoogle ScholarPubMed
Consroe, P, Sandyk, R, Snider, SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30: 277–282.CrossRefGoogle ScholarPubMed
Delnooz, CCS, van de Warrenburg, BPC (2012) Current and future medical treatment in primary dystonia. Ther Adv Neurol Disord 5: 221–240.CrossRefGoogle ScholarPubMed
Dressler, D, Altenmueller, E, Bhidayasiri, R, Boholega, S, Chana, P, Chung, TM, Frucht, S, Garcia-Ruiz, PJ, Kaelin, A, Kaji, R, Kanovsky, P, Laskawi, R, Micheli, F, Orlova, O, Relja, M, Rosales, R, Slawek, J, Timerbaeva, S, Warner, TT, Adib Saberi, F (2015a) Strategies for treatment of dystonia. J Neural Transm 123: 251–258.CrossRefGoogle ScholarPubMed
Dressler, D, Berweck, S, Chatzikalfas, A, Ebke, M, Frank, B, Hesse, S, Huber, M, Krauss, JK, Mücke, K-H, Nolte, A, Oelmann, H-D, Schönle, PW, Schmutzler, M, Pickenbrock, H, Van der Ven, C, Veelken, N, Vogel, M, Vogt, T, Adib Saberi, F (2015b) Intrathecal baclofen therapy in Germany: proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders consensus meeting. J Neural Transm 122:1573–1579.CrossRefGoogle Scholar
Fox, SH, Kellett, M, Moore, AP, Crossman, AR, Brotchie, JM (2002) Randomised, double blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145–149.CrossRefGoogle ScholarPubMed
Grassi, E, Latorraca, S, Piacentini, S, Marini, P, Sorbi, S (2000) Risperidone in idiopathic and symptomatic dystonia: preliminary experience. Neurol Sci 21:121–123.CrossRefGoogle ScholarPubMed
Greene, P (1992) Baclofen in the treatment of dystonia. Clin Neuropharmacol 15: 276–288.CrossRefGoogle ScholarPubMed
Greene, P, Shale, H, Fahn, S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3: 46–60.CrossRefGoogle ScholarPubMed
Isgreen, WP (1976) Carbamazepine in torsion dystonia. Adv Neurol 14: 411–416.Google Scholar
Jankovic, J (2006) Treatment of dystonia. Lancet Neurol 5: 864–872.CrossRefGoogle ScholarPubMed
Jankovic, J (2009) Treatment of hyperkinetic movement disorders. Lancet Neurol 8: 844–855.CrossRefGoogle ScholarPubMed
Jankovic, J (2013) Medical treatment of dystonia. Mov Disord 28: 1001–1012.CrossRefGoogle ScholarPubMed
Kluger, B, Triolo, P, Jones, W, Jankovic, J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30: 313–327.CrossRefGoogle ScholarPubMed
Koppel, BS, Brust, JC, Fife, T, Bronstein, J, Youssof, S, Gronseth, G, Gloss, D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 82: 1556–1563.CrossRefGoogle ScholarPubMed
Lang, AE (1988) Dopamine agonists and antagonists in treatment of idiopathic dystonia. Adv Neurol 50: 561–570.Google ScholarPubMed
Lin, JJ, Chang, DC (2004) Improvement of generalized dystonia by olanzapine treatment. J Clin Neurosci 11: 84–86.CrossRefGoogle Scholar
Lucetti, C, Nuti, A, Gambaccini, G, Bernardini, S, Brotini, S, Manca, ML, Bonuccelli, U (2000) Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol 23: 186–189.CrossRefGoogle ScholarPubMed
Marsden, CD, Marion, MH, Quinn, N (1984) The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 47: 1166–1173.CrossRefGoogle ScholarPubMed
Nutt, JG, Hammerstad, JP, Carter, JH, deGarmo, PL (1985) Lisuride treatment of focal dystonias. Neurology 35: 1242–1243.CrossRefGoogle ScholarPubMed
Thiel, A, Dressler, D, Kistel, C, Rüther, E (1994) Clozapine treatment of spasmodic torticollis. Neurology 44: 957–958.CrossRefGoogle ScholarPubMed
van der Plus, AA, Schilder, JC, Marinus, J, van Hilten, JJ (2013) An explanatory study evaluating the muscle relaxant effects of intramuscular magnesium sulphate for dystonia in complex regional pain syndrome. J Pain 14: 1341–1348.CrossRefGoogle Scholar
Zuddas, A, Cianchetti, C (1996) Efficacy of risperidone in idiopathic segmental dystonia. Lancet 347: 127–128.CrossRefGoogle ScholarPubMed

References

Albright, AL (1996) Spasticity and movement disorders in cerebral palsy. J Child Neurol 11(Suppl. 1), S1–4.Google ScholarPubMed
Battini, R, Casarano, M, Sgandurra, G, Olivieri, I, Di Pietro, R, Romeo, DM, Mercuri, E, Cioni, G (2014) Responsiveness of the MD-childhood rating scale in dyskinetic cerebral palsy patients undergoing anticholinergic treatment. Eur J Paediatr Neurol 18, 698–703.CrossRefGoogle ScholarPubMed
Ben-Pazi, H (2011) Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. J Child Neurol 26, 810–816.CrossRefGoogle ScholarPubMed
Brans, JW, Lindeboom, R, Snoek, JW, Zwarts, MJ, van Weerden, TW, Brunt, ER, van Hilten, JJ, van der Kamp, W, Prins, MH, Speelman, JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46, 1066–1072.CrossRefGoogle ScholarPubMed
Burke, RE, Fahn, S, Marsden, CD (1986) Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36, 160–164.CrossRefGoogle ScholarPubMed
Carranza-del Rio, J, Clegg, NJ, Moore, A, Delgado, MR (2011) Use of trihexyphenidyl in children with cerebral palsy. Pediatr Neurol 44, 202–206.CrossRefGoogle ScholarPubMed
Chuang, C, Fahn, S, Frucht, SJ (2002) The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry 72, 59–67.CrossRefGoogle ScholarPubMed
Deuschl, G (2003) Dystonic tremor. Rev Neurol (Paris) 159, 900–905.Google ScholarPubMed
Eskow Jaunarajs, KL, Bonsi, P, Chesselet, MF, Standaert, DG, Pisani, A (2015) Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Prog Neurobiol 127–128C, 91–107.CrossRefGoogle ScholarPubMed
Fahn, S (1983) High dosage anticholinergic therapy in dystonia. Neurology 33, 1255–1261.CrossRefGoogle ScholarPubMed
Fasano, A, Bove, F, Lang, AE (2014) The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 85, 759–769.CrossRefGoogle ScholarPubMed
Granana, N, Ferrea, M, Scorticati, MC, Diaz, S, Arrebola, M, Torres, L, Micheli, F (1999) Beneficial effects of diphenhydramine in dystonia. Medicina (B Aires) 59, 38–42.Google ScholarPubMed
Greene, P, Shale, H, Fahn, S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3, 46–60.CrossRefGoogle ScholarPubMed
Hoon, AH, Jr, Freese, PO, Reinhardt, EM, Wilson, MA, Lawrie, WT, Jr, Harryman, SE, Pidcock, FS, Johnston, MV (2001) Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr Neurol 25, 55–58.CrossRefGoogle ScholarPubMed
Hughes, AJ, Lees, AJ, Marsden, CD (1991) Paroxysmal dystonic head tremor. Mov Disord 6, 85–86.CrossRefGoogle ScholarPubMed
Jankovic, J (2013) Medical treatment of dystonia. Mov Disord 28, 1001–1012.CrossRefGoogle ScholarPubMed
Kostic, V, Przedborski, S, Jackson-Lewis, V, Cadet, JL, Burke, RE (1991) Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on striatal muscarinic cholinergic receptors and high-affinity choline uptake sites: a quantitative autoradiographic study. J Neurochem 57, 1962–1970.CrossRefGoogle ScholarPubMed
Lang, AE (1986) High dose anticholinergic therapy in adult dystonia. Can J Neurol Sci 13, 42–46.CrossRefGoogle ScholarPubMed
Maltese, M, Martella, G, Madeo, G, Fagiolo, I, Tassone, A, Ponterio, G, Sciamanna, G, Burbaud, P, Conn, PJ, Bonsi, P, Pisani, A (2014). Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors. Mov Disord 29, 1655–1665.CrossRefGoogle ScholarPubMed
Martella, G, Tassone, A, Sciamanna, G, Platania, P, Cuomo, D, Viscomi, MT, Bonsi, P, Cacci, E, Biagioni, S, Usiello, A, Bernardi, G, Sharma, N, Standaert, DG, Pisani, A (2009) Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 132, 2336–2349.CrossRefGoogle ScholarPubMed
Oztekin, NS, Saygi, SS, Dalkara, T, Senses, I, Zileli, T (1991) High dose anticholinergic therapy (biperiden) in dystonia. Clin Neurol Neurosurg 93, 35–37.CrossRefGoogle Scholar
Pettigrew, LC, Jankovic, J (1985) Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry 48, 650–657.CrossRefGoogle Scholar
Pidcock, FS, Hoon, AH, Jr, Johnston, MV (1999) Trihexyphenidyl in posthemorrhagic dystonia: motor and language effects. Pediatr Neurol 20, 219–222.CrossRefGoogle ScholarPubMed
Pisani, A, Bernardi, G, Ding, J, Surmeier, DJ (2007) Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30, 545–553.CrossRefGoogle ScholarPubMed
Poewe, W, Lees, AJ, Steiger, D, Stern, GM (1987) Foot dystonia in Parkinson’s disease: clinical phenomenology and neuropharmacology. Adv Neurol 45, 357–360.Google ScholarPubMed
Poewe, WH, Lees, AJ, Stern, GM (1988) Dystonia in Parkinson’s disease: clinical and pharmacological features. Ann Neurol 23, 73–78.CrossRefGoogle ScholarPubMed
Povlsen, UJ, Pakkenberg, H (1990) Effect of intravenous injection of biperiden and clonazepam in dystonia. Mov Disord 5, 27–31.CrossRefGoogle ScholarPubMed
Rice, J, Waugh, MC (2009) Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol 24, 176–182.CrossRefGoogle ScholarPubMed
Robottom, BJ, Reich, SG (2011) Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review. Neurologist 17, 340–341.CrossRefGoogle ScholarPubMed
Rosenbaum, F, Jankovic, J (1988) Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology 38, 522–527.CrossRefGoogle ScholarPubMed
Sanger, TD, Bastian, A, Brunstrom, J, Damiano, D, Delgado, M, Dure, L, Gaebler-Spira, D, Hoon, A, Mink, JW, Sherman-Levine, S, Welty, LJ, Child Motor Study Group (2007) Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 22, 530–537.CrossRefGoogle ScholarPubMed
Schneider, SA, Bhatia, KP (2007) The entity of jaw tremor and dystonia. Mov Disord 22, 1491–1495.CrossRefGoogle ScholarPubMed
Taylor, AE, Lang, AE, Saint-Cyr, JA, Riley, DE, Ranawaya, R (1991) Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin Neuropharmacol 14, 62–77.CrossRefGoogle ScholarPubMed
Thenganatt, MA, Jankovic, J (2014) Treatment of dystonia. Neurotherapeutics 11, 139–152.CrossRefGoogle ScholarPubMed
Truong, DD, Sandroni, P, van den Noort, S, Matsumoto, RR (1995). Diphenhydramine is effective in the treatment of idiopathic dystonia. Arch Neurol 52, 405–407.CrossRefGoogle ScholarPubMed
Van der Burg, JJ, Jongerius, PH, Van Hulst, K, Van Limbeek, J, Rotteveel, JJ (2006) Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev Med Child Neurol 48, 103–107.CrossRefGoogle ScholarPubMed
van’t Groenewout, JL, Stone, MR, Vo, VN, Truong, DD, Matsumoto, RR (1995) Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine. Exp Neurol 134, 253–260.CrossRefGoogle ScholarPubMed
Vidailhet, M (2013) Treatment of movement disorders in dystonia-choreoathtosis cerebral palsy. Handb Clin Neurol 111, 197–202.CrossRefGoogle ScholarPubMed

References

Asher, SW, Aminoff, MJ (1981). Tetrabenazine and movement disorders. Neurology 31:1051–1054.CrossRefGoogle ScholarPubMed
Fasano, A, Bove, F, Lang, AE (2014). The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 85:759–769.CrossRefGoogle ScholarPubMed
Frank, S, Ondo, W, Fahn, S, Hunter, C, Oakes, D, Plumb, S, Marshall, F, Shoulson, I, Eberly, S, Walker, F, Factor, S, Hunt, V, Shinaman, A, Jankovic, J (2008). A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 31:127–133.CrossRefGoogle ScholarPubMed
Godwin-Austen, RB (1979). The treatment of the choreas and athetotic dystonias. J R Coll Physicians Lond 13:35–38.Google ScholarPubMed
Huntington Study Group (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366–372.CrossRef
Jankovic, J (1982). Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 11:41–47.CrossRefGoogle ScholarPubMed
Jankovic, J (1995). Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 18:197–214.CrossRefGoogle ScholarPubMed
Jankovic, J, Beach, J (1997). Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358–362.CrossRefGoogle ScholarPubMed
Jankovic, J, Orman, J (1988). Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38:391–394.CrossRefGoogle ScholarPubMed
Kazamatsuri, H, Chien, C, Cole, JO (1972). Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 27:95–99.CrossRefGoogle ScholarPubMed
Kazamatsuri, H, Chien, CP, Cole, JO (1973). Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 130:479–483.Google ScholarPubMed
Kenney, C, Hunter, C, Mejia, N, Jankovic, J (2006). Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 29:259–264.CrossRefGoogle ScholarPubMed
Kenney, C, Hunter, C, Jankovic, J (2007). Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 22:193–197.CrossRefGoogle ScholarPubMed
LeWitt, PA (2013). Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 36:92–93.CrossRefGoogle ScholarPubMed
Luciano, AY, Jinnah, HA, Pfeiffer, RF, Truong, DD, Nance, MA, LeDoux, MS (2014). Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord 20:1423–1426.CrossRefGoogle ScholarPubMed
Marsden, CD, Marion, MH, Quinn, N (1984). The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 47:1166–1173.CrossRefGoogle ScholarPubMed
Ondo, WG, Hanna, PA, Jankovic, J (1999). Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 156:1279–1281.Google ScholarPubMed
Paleacu, D, Giladi, N, Moore, O, Stern, A, Honigman, S, Badarny, S (2004). Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 27:230–233.CrossRefGoogle ScholarPubMed
Schrader, C, Dengler, R, Dressler, D (2010). Tetrabenazin in der Behandlung hyperkinetischer Bewegungsstörungen. Psychopharmakotherapie 17:85–90.Google Scholar
Soares-Weiser, K, Fernandez, HH (2007). Tardive dyskinesia. Semin Neurol 27:159–169.CrossRefGoogle ScholarPubMed
Swash, M, Roberts, AH, Zakko, H, Heathfield, KW (1972). Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 35:186–191.CrossRefGoogle ScholarPubMed
Watson, MW, Skelton, D, Jamali, F (1988). Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 33:11–13.CrossRefGoogle ScholarPubMed

References

Abdenur, JE, Abeling, N, Specola, N, Jorge, L, Schenone, AB, van Cruchten, AC, et al. 2006. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Molecular Genetics and Metabolism 87(1):48–53.CrossRefGoogle ScholarPubMed
Abeling, NG, Duran, M, Bakker, HD, Stroomer, L, Thony, B, Blau, N, et al. 2006. Sepiapterin reductase deficiency: an autosomal recessive DOPA-responsive dystonia. Molecular Genetics and Metabolism 89(1–2):116–120.CrossRefGoogle ScholarPubMed
al Aqeel, A, Ozand, PT, Gascon, G, Nester, M, al Nasser, M, Brismar, J, et al. 1991. Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. Neurology 41(5):730–737.CrossRefGoogle ScholarPubMed
Allen, GF, Land, JM, Heales, SJ. 2009. A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Molecular Genetics and Metabolism 97(1):6–14.CrossRefGoogle ScholarPubMed
Allen, GF, Neergheen, V, Oppenheim, M, Fitzgerald, JC, Footitt, E, Hyland, K, et al. 2010. Pyridoxal 5′-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states. Journal of Neurochemistry 114(1):87–96.Google ScholarPubMed
Anselm, IA, Darras, BT. 2006. Catecholamine toxicity in aromatic L-amino acid decarboxylase deficiency. Pediatric Neurology 35(2):142–144.CrossRefGoogle ScholarPubMed
Arrabal, L, Teresa, L, Sanchez-Alcudia, R, Castro, M, Medrano, C, Gutierrez-Solana, L, et al. 2011. Genotype–phenotype correlations in sepiapterin reductase deficiency: a splicing defect accounts for a new phenotypic variant. Neurogenetics 12(3):183–191.CrossRefGoogle ScholarPubMed
Bandmann, O, Wood, NW. 2002. Dopa-responsive dystonia: the story so far. Neuropediatrics 33(1):1–5.CrossRefGoogle ScholarPubMed
Blau, N, Ichinose, H, Nagatsu, T, Heizmann, CW, Zacchello, F, Burlina, AB. 1995. A missense mutation in a patient with guanosine triphosphate cyclohydrolase I deficiency missed in the newborn screening program. The Journal of Pediatrics 126(3):401–405.CrossRefGoogle Scholar
Bruggemann, N, Spiegler, J, Hellenbroich, Y, Opladen, T, Schneider, SA, Stephani, U, et al. 2012. Beneficial prenatal levodopa therapy in autosomal recessive guanosine triphosphate cyclohydrolase 1 deficiency. Archives of Neurology 69(8):1071–1075.CrossRefGoogle ScholarPubMed
Brun, L, Ngu, LH, Keng, WT, Ch’ng, GS, Choy, YS, Hwu, WL, et al. 2010. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75(1):64–71.CrossRefGoogle ScholarPubMed
Cai, C, Shi, W, Zeng, Z, Zhang, M, Ling, C, Chen, L, et al. 2013. GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. PLoS One 8(6):e65215.CrossRefGoogle ScholarPubMed
Cao, L, Zheng, L, Tang, WG, Xiao, Q, Zhang, T, Tang, HD, et al. 2010. Four novel mutations in the GCH1 gene of Chinese patients with dopa-responsive dystonia. Movement Disorders: Official Journal of the Movement Disorder Society 25(6):755–760.CrossRefGoogle ScholarPubMed
Chang, YT, Sharma, R, Marsh, JL, McPherson, JD, Bedell, JA, Knust, A, et al. 2004. Levodopa-responsive aromatic L-amino acid decarboxylase deficiency. Annals of Neurology 55(3):435–438.CrossRefGoogle ScholarPubMed
Chi, CS, Lee, HF, Tsai, CR. 2012. Tyrosine hydroxylase deficiency in Taiwanese infants. Pediatric Neurology 46(2):77–82.CrossRefGoogle ScholarPubMed
Chieng, KS, Hussain, N, Gosalakkal, JA. 2007. Dystonia during feeding as an early sign of dopa-responsive dystonia. Pediatric Neurology 37(3):215–217.CrossRefGoogle ScholarPubMed
Clot, F, Grabli, D, Cazeneuve, C, Roze, E, Castelnau, P, Chabrol, B, et al. 2009. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain: A Journal of Neurology 132(Pt 7):1753–1763.CrossRefGoogle ScholarPubMed
Concolino, D, Muzzi, G, Rapsomaniki, M, Moricca, MT, Pascale, MG, Strisciuglio, P. 2008. Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients. Journal of Inherited Metabolic Disease 31(Suppl. 2):S193–S197.CrossRefGoogle ScholarPubMed
Coughlin, CR, 2nd, Hyland, K, Randall, R, Ficicioglu, C. 2013. Dihydropteridine reductase deficiency and treatment with tetrahydrobiopterin: a case report. JIMD Reports 10:53–56.CrossRefGoogle ScholarPubMed
Davis, MD, Ribeiro, P, Tipper, J, Kaufman, S. 1992. ‘7-tetrahydrobiopterin’, a naturally occurring analogue of tetrahydrobiopterin, is a cofactor for and a potential inhibitor of the aromatic amino acid hydroxylases. Proceedings of the National Academy of Sciences of the United States of America 89(21):10109–10113.CrossRefGoogle Scholar
de la Fuente-Fernandez, R. 1999. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations. Clinical Neuropharmacology 22(4):216–219.Google ScholarPubMed
de Rijk-Van Andel, JF, Gabreels, FJ, Geurtz, B, Steenbergen-Spanjers, GC, van Den Heuvel, LP, Smeitink, JA, et al. 2000. L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology 55(12):1926–1928.CrossRefGoogle ScholarPubMed
Del, P, Nassogne, MC, van Gennip, AH, van Cruchten, AC, Billatte de Villemeur, T, Cretz, M, et al. 2000. Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation. Journal of Inherited Metabolic Disease 23(8):819–825.Google Scholar
Demos, MK, Waters, PJ, Vallance, HD, Lillquist, Y, Makhseed, N, Hyland, K, et al. 2005. 6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia. Annals of Neurology 58(1):164–167.CrossRefGoogle ScholarPubMed
Dhondt, J-L, Farriaux, J-P, Boudha, A, Largillière, C, Ringel, J, Roger, M-M, et al. 1985. Neonatal hyperphenylalaninemia presumably caused by guanosine triphosphate-cyclohydrolase deficiency. The Journal of Pediatrics. 106(6):954–956.CrossRefGoogle ScholarPubMed
Diepold, K, Schutz, B, Rostasy, K, Wilken, B, Hougaard, P, Guttler, F, et al. 2005. Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections. Movement Disorders: Official Journal of the Movement Disorder Society 20(6):764–767.CrossRefGoogle ScholarPubMed
Dill, P, Wagner, M, Somerville, A, Thony, B, Blau, N, Weber, P. 2012. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia – hallmarks of sepiapterin reductase deficiency. Neurology 78(5):e29–e32.CrossRefGoogle ScholarPubMed
Dionisi-Vici, C, Hoffmann, GF, Leuzzi, V, Hoffken, H, Brautigam, C, Rizzo, C, et al. 2000. Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. The Journal of Pediatrics 136(4):560–562.CrossRefGoogle Scholar
Doummar, D, Clot, F, Vidailhet, M, Afenjar, A, Durr, A, Brice, A, et al. 2009. Infantile hypokinetic-hypotonic syndrome due to two novel mutations of the tyrosine hydroxylase gene. Movement Disorders: Official Journal of the Movement Disorder Society 24(6):943–945.CrossRefGoogle ScholarPubMed
Dudesek, A, Roschinger, W, Muntau, AC, Seidel, J, Leupold, D, Thony, B, et al. 2001. Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. European Journal of Pediatrics 160(5):267–276.Google ScholarPubMed
Echenne, B, Roubertie, A, Assmann, B, Lutz, T, Penzien, JM, Thony, B, et al. 2006. Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy. Pediatric Neurology 35(5):308–313.CrossRefGoogle ScholarPubMed
Fiumara, A, Brautigam, C, Hyland, K, Sharma, R, Lagae, L, Stoltenborg, B, et al. 2002. Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria: clinical and laboratory findings in response to different therapies. Neuropediatrics 33(4):203–208.CrossRefGoogle ScholarPubMed
Friedman, J, Hyland, K, Blau, N, MacCollin, M. 2006. Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology 67(11):2032–2035.CrossRefGoogle ScholarPubMed
Friedman, J, Roze, E, Abdenur, JE, Chang, R, Gasperini, S, Saletti, V, et al. 2012. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Annals of Neurology 71(4):520–530.CrossRefGoogle ScholarPubMed
Furukawa, Y, Shimadzu, M, Rajput, AH, Shimizu, Y, Tagawa, T, Mori, H, et al. 1996. GTP-cyclohydrolase I gene mutations in hereditary progressive and dopa-responsive dystonia. Annals of Neurology 39(5):609–617.CrossRefGoogle ScholarPubMed
Furukawa, Y, Kish, SJ, Bebin, EM, Jacobson, RD, Fryburg, JS, Wilson, WG, et al. 1998. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Annals of Neurology 44(1):10–16.CrossRefGoogle ScholarPubMed
Furukawa, Y, Filiano, JJ, Kish, SJ. 2004. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Movement Disorders: Official Journal of the Movement Disorder Society 19(10):1256–1258.CrossRefGoogle ScholarPubMed
Garavaglia, B, Invernizzi, F, Carbone, ML, Viscardi, V, Saracino, F, Ghezzi, D, et al. 2004. GTP-cyclohydrolase I gene mutations in patients with autosomal dominant and recessive GTP-CH1 deficiency: identification and functional characterization of four novel mutations. Journal of Inherited Metabolic Disease 27(4):455–463.CrossRefGoogle ScholarPubMed
Giovanniello, T, Leuzzi, V, Carducci, C, Carducci, C, Sabato, ML, Artiola, C, et al. 2007. Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics 38(4):213–215.CrossRefGoogle ScholarPubMed
Giovanniello, T, Claps, D, Carducci, C, Carducci, C, Blau, N, Vigevano, F, et al. 2012. A new tyrosine hydroxylase genotype associated with early-onset severe encephalopathy. Journal of Child Neurology 27(4):523–525.CrossRefGoogle ScholarPubMed
Gizewska, M, Hnatyszyn, G, Sagan, L, Cyrylowski, L, Zekanowski, C, Modrzejewska, M, et al. 2009. Maternal tetrahydrobiopterin deficiency: the course of two pregnancies and follow-up of two children in a mother with 6-pyruvoyl-tetrahydropterin synthase deficiency. Journal of Inherited Metabolic Disease 32(Suppl. 1):S83–S89.CrossRefGoogle Scholar
Goldstein, DS, Hahn, SH, Holmes, C, Tifft, C, Harvey-White, J, Milstien, S, et al. 1995. Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency. Journal of Neurochemistry 64(6):2810–2813.CrossRefGoogle ScholarPubMed
Grattan-Smith, PJ, Wevers, RA, Steenbergen-Spanjers, GC, Fung, VS, Earl, J, Wilcken, B. 2002. Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Movement Disorders: Official Journal of the Movement Disorder Society 17(2):354–359.CrossRefGoogle ScholarPubMed
Grimes, DA, Barclay, CL, Duff, J, Furukawa, Y, Lang, AE. 2002. Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture? Journal of Neurology, Neurosurgery, and Psychiatry 72(6):801–804.CrossRefGoogle Scholar
Hagenah, J, Saunders-Pullman, R, Hedrich, K, Kabakci, K, Habermann, K, Wiegers, K, et al. 2005. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 64(5):908–911.CrossRefGoogle ScholarPubMed
Han, B, Zou, H, Han, B, Zhu, W, Cao, Z, Liu, Y. 2014. Diagnosis, treatment and follow-up of patients with tetrahydrobiopterin deficiency in Shandong province, China. Brain & Development 37:592–598.CrossRefGoogle ScholarPubMed
Harwood, G, Hierons, R, Fletcher, NA, Marsden, CD. 1994. Lessons from a remarkable family with dopa-responsive dystonia. Journal of Neurology, Neurosurgery, and Psychiatry 57(4):460–463.CrossRefGoogle ScholarPubMed
Haugarvoll, K, Bindoff, LA. 2011. A novel compound heterozygous tyrosine hydroxylase mutation (p.R441P) with complex phenotype. Journal of Parkinson’s Disease 1(1):119–122.Google ScholarPubMed
Haussler, M, Hoffmann, GF, Wevers, RA. 2001. L-dopa and selegiline for tyrosine hydroxylase deficiency. The Journal of Pediatrics 138(3):451–452.CrossRefGoogle ScholarPubMed
Hoffmann, GF, Assmann, B, Brautigam, C, Dionisi-Vici, C, Haussler, M, de Klerk, JB, et al. 2003. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Annals of Neurology 54(Suppl. 6):S56–S65.CrossRefGoogle ScholarPubMed
Horvath, GA, Stockler-Ipsiroglu, SG, Salvarinova-Zivkovic, R, Lillquist, YP, Connolly, M, Hyland, K, et al. 2008. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Molecular Genetics and Metabolism 94(1):127–131.CrossRefGoogle ScholarPubMed
Hu, FY, Xu, YM, Yu, LH, Ma, MY, He, XH, Zhou, D. 2011. A novel missense mutation in GTP cyclohydrolase I (GCH1) gene causes dopa-responsive dystonia in Chinese Han population. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 18(2):362–364.CrossRefGoogle ScholarPubMed
Hwu, WL, Wang, PJ, Hsiao, KJ, Wang, TR, Chiou, YW, Lee, YM. 1999. Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I mutation. Human Genetics 105(3):226–230.CrossRefGoogle ScholarPubMed
Hyland, K, Clayton, PT. 1990. Aromatic amino acid decarboxylase deficiency in twins. Journal of Inherited Metabolic Disease 13(3):301–304.CrossRefGoogle ScholarPubMed
Hyland, K, Surtees, RA, Rodeck, C, Clayton, PT. 1992. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42(10):1980–1988.Google ScholarPubMed
Ihara, M, Kohara, N, Urano, F, Ichinose, H, Takao, S, Nishida, T, et al. 2002. Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient. Neurology 59(7):1102–1104.CrossRefGoogle Scholar
Imamura, T, Okano, Y, Shintaku, H, Hase, Y, Isshiki, G. 1999. Molecular characterization of 6-pyruvoyl-tetrahydropterin synthase deficiency in Japanese patients. Journal of Human Genetics 44(3):163–168.CrossRefGoogle ScholarPubMed
Irons, M, Levy, HL, O’Flynn, ME, Stack, CV, Langlais, PJ, Butler, IJ, et al. 1987. Folinic acid therapy in treatment of dihydropteridine reductase deficiency. The Journal of Pediatrics 110(1):61–67.CrossRefGoogle ScholarPubMed
Jaggi, L, Zurfluh, MR, Schuler, A, Ponzone, A, Porta, F, Fiori, L, et al. 2008. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Molecular Genetics and Metabolism 93(3):295–305.CrossRefGoogle ScholarPubMed
Jankovic, J. 2006. Treatment of dystonia. Lancet Neurology 5(10):864–872.CrossRefGoogle ScholarPubMed
Janssen, RJ, Wevers, RA, Haussler, M, Luyten, JA, Steenbergen-Spanjers, GC, Hoffmann, GF, et al. 2000. A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Annals of Human Genetics 64(Pt 5):375–382.CrossRefGoogle Scholar
Jardim, LB, Giugliani, R, Coelho, JC, Dutra-Filho, CS, Blau, N. 1994. Possible high frequency of tetrahydrobiopterin deficiency in south Brazil. Journal of Inherited Metabolic Disease 17(2):223–229.CrossRefGoogle ScholarPubMed
Jarman, PR, Bandmann, O, Marsden, CD, Wood, NW. 1997. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. Journal of Neurology, Neurosurgery, and Psychiatry 63(3):304–308.CrossRefGoogle ScholarPubMed
Jeon, BS, Jeong, JM, Park, SS, Kim, JM, Chang, YS, Song, HC, et al. 1998. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Annals of Neurology 43(6):792–800.CrossRefGoogle Scholar
Kaindl, AM, Steinberger, D, Heubner, G, Müller, U, Blau, N, Neubert, K, et al. 2005. Phenotype of five patients with dopa-responsive dystonia and mutations in GCH1. Journal of Pediatric Neurology 3(2):83–87.Google Scholar
Karkheiran, S, Hubert, B, Moghaddam, H, Darvish, H, Paisan-Ruiz, C. 2013. Phenotypic heterogeneity and full penetrance in a family with dopa-responsive dystonia. Clinical Genetics 83(4):392–394.CrossRefGoogle Scholar
Koht, J, Rengmark, A, Opladen, T, Bjornara, KA, Selberg, T, Tallaksen, CM, et al. 2014. Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene. Acta Neurologica Scandinavica Supplementum 198:7–12.CrossRefGoogle Scholar
Korenke, GC, Christen, HJ, Hyland, K, Hunneman, DH, Hanefeld, F. 1997. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. European Journal of Paediatric Neurology: Official Journal of the European Paediatric Neurology Society 1(2–3):67–71.CrossRefGoogle ScholarPubMed
Kurian, MA, Gissen, P, Smith, M, Heales, S, Jr, Clayton, PT. 2011. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurology 10(8):721–733.CrossRefGoogle ScholarPubMed
Kusmierska, K, Jansen, EE, Jakobs, C, Szymanska, K, Malunowicz, E, Meilei, D, et al. 2009. Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up. Journal of Inherited Metabolic Disease 32(Suppl. 1):S5–S10.CrossRefGoogle Scholar
Lee, JY, Yang, HJ, Kim, JM, Jeon, BS. 2013. Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia. Parkinsonism & Related Disorders 19(12):1156–1159.CrossRefGoogle ScholarPubMed
Lee, LK, Cheung, KM, Cheng, WW, Ko, CH, Lee, HH, Ching, CK, et al. 2014. A rare cause of severe diarrhoea diagnosed by urine metabolic screening: aromatic L-amino acid decarboxylase deficiency. Hong Kong Medical Journal = Xianggang yi xue za zhi/Hong Kong Academy of Medicine 20(2):161–164.Google ScholarPubMed
Lee, NC, Cheng, LY, Liu, TT, Hsiao, KJ, Chiu, PC, Niu, DM. 2006. Long-term follow-up of Chinese patients who received delayed treatment for 6-pyruvoyl-tetrahydropterin synthase deficiency. Molecular Genetics and Metabolism 87(2):128–134.CrossRefGoogle ScholarPubMed
Lee, WW, Jeon, BS. 2014. Clinical spectrum of dopa-responsive dystonia and related disorders. Current Neurology and Neuroscience Reports 14(7):461.CrossRefGoogle ScholarPubMed
Leeming, RJ, Harpey, JP, Brown, SM, Blair, JA. 1982. Tetrahydrofolate and hydroxocobolamin in the management of dihydropteridine reductase deficiency. Journal of Mental Deficiency Research 26(Pt 1):21–25.Google ScholarPubMed
Leuzzi, V, Carducci, CA, Carducci, CL, Pozzessere, S, Burlina, A, Cerone, R, et al. 2010. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clinical Genetics 77(3):249–257.CrossRefGoogle ScholarPubMed
Leuzzi, V, Carducci, C, Tolve, M, Giannini, MT, Angeloni, A, Carducci, C. 2013. Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology 81(24):2141–2142.CrossRefGoogle ScholarPubMed
Leuzzi, V, Mastrangelo, M, Polizzi, A, Artiola, C, van Kuilenburg, AB, Carducci, C, et al. 2014. Report of two never treated adult sisters with aromatic L-amino acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype? JIMD Reports 15:39–45.Google ScholarPubMed
Lin, Y, Wang, DN, Chen, WJ, Lin, X, Lin, MT, Wang, N. 2014. Growth hormone deficiency in a dopa-responsive dystonia patient with a novel mutation of guanosine triphosphate cyclohydrolase 1 gene. Journal of Child Neurology 30:796–799.CrossRefGoogle Scholar
Ling, H, Polke, JM, Sweeney, MG, Haworth, A, Sandford, CA, Heales, SJ, et al. 2011. An intragenic duplication in guanosine triphosphate cyclohydrolase-1 gene in a dopa-responsive dystonia family. Movement Disorders: Official Journal of the Movement Disorder Society 26(5):905–909.CrossRefGoogle Scholar
Lipson, AH, Earl, JW, Wilcken, B, Yu, JS, O’Halloran, M, Cotton, RG. 1991. Successful treatment of dihydropteridine reductase deficiency, with an interesting effect of 5-hydroxytryptophan deficiency on sleep patterns. Journal of Inherited Metabolic Disease 14(1):49–52.CrossRefGoogle ScholarPubMed
Liu, KM, Liu, TT, Lee, NC, Cheng, LY, Hsiao, KJ, Niu, DM. 2008. Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. Archives of Neurology 65(3):387–392.CrossRefGoogle ScholarPubMed
Liu, X, Zhang, SS, Fang, DF, Ma, MY, Guo, XY, Yang, Y, et al. 2010. GCH1 mutation and clinical study of Chinese patients with dopa-responsive dystonia. Movement Disorders: Official Journal of the Movement Disorder Society 25(4):447–451.CrossRefGoogle ScholarPubMed
Longo, N. 2009. Disorders of biopterin metabolism. Journal of Inherited Metabolic Disease 32(3):333–342.CrossRefGoogle ScholarPubMed
Lopez-Laso, E, Ochoa-Sepulveda, JJ, Ochoa-Amor, JJ, Bescansa-Heredero, E, Camino-Leon, R, Gascon-Jimenez, FJ, et al. 2009. Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Cordoba (southern Spain). Journal of Neurology 256(11):1816–1824.CrossRefGoogle Scholar
Lopez-Laso, E, Beyer, K, Opladen, T, Artuch, R, Saunders-Pullman, R. 2012. Dyskinesias as a limiting factor in the treatment of Segawa disease. Pediatric Neurology 46(6):404–406.CrossRefGoogle ScholarPubMed
Lu, DY, Ye, J, Han, LS, Qiu, WJ, Zhang, HW, Zhou, JD, et al. 2014. QDPR gene mutation and clinical follow-up in Chinese patients with dihydropteridine reductase deficiency. World Journal of Pediatrics 10(3):219–226.CrossRefGoogle ScholarPubMed
Maller, A, Hyland, K, Milstien, S, Biaggioni, I, Butler, IJ. 1997. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. Journal of Child Neurology 12(6):349–354.CrossRefGoogle ScholarPubMed
Manegold, C, Hoffmann, GF, Degen, I, Ikonomidou, H, Knust, A, Laass, MW, et al. 2009. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. Journal of Inherited Metabolic Disease 32(3):371–380.CrossRefGoogle ScholarPubMed
Mastrangelo, M, Caputi, C, Galosi, S, Giannini, MT, Leuzzi, V. 2013. Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Movement Disorders: Official Journal of the Movement Disorder Society 28(4):556–557.CrossRefGoogle ScholarPubMed
Moller, LB, Romstad, A, Paulsen, M, Hougaard, P, Ormazabal, A, Pineda, M, et al. 2005. Pre- and postnatal diagnosis of tyrosine hydroxylase deficiency. Prenatal Diagnosis 25(8):671–675.CrossRefGoogle ScholarPubMed
Naiya, T, Misra, AK, Biswas, A, Das, SK, Ray, K, Ray, J. 2012. Occurrence of GCH1 gene mutations in a group of Indian dystonia patients. Journal of Neural Transmission 119(11):1343–1350.CrossRefGoogle Scholar
Nardocci, N, Zorzi, G, Blau, N, Fernandez Alvarez, E, Sesta, M, Angelini, L, et al. 2003. Neonatal dopa-responsive extrapyramidal syndrome in twins with recessive GTPCH deficiency. Neurology 60(2):335–337.CrossRefGoogle ScholarPubMed
Neville, BG, Parascandalo, R, Farrugia, R, Felice, A. 2005. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain: A Journal of Neurology 128(Pt 10):2291–2296.CrossRefGoogle ScholarPubMed
Ng, J, Heales, SJ, Kurian, MA. 2014. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. Paediatric Drugs 16(4):275–291.CrossRefGoogle ScholarPubMed
Niu, DM. 2011. Disorders of BH4 metabolism and the treatment of patients with 6-pyruvoyl-tetrahydropterin synthase deficiency in Taiwan. Brain & Development 33(10):847–855.CrossRefGoogle ScholarPubMed
Nygaard, TG, Marsden, CD, Duvoisin, RC. 1988. Dopa-responsive dystonia. Advances in Neurology 50:377–384.Google ScholarPubMed
Ogawa, A, Kanazawa, M, Takayanagi, M, Kitani, Y, Shintaku, H, Kohno, Y. 2008. A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Brain & Development 30(1):82–85.CrossRefGoogle ScholarPubMed
Opladen, T, Hoffmann, G, Horster, F, Hinz, AB, Neidhardt, K, Klein, C, et al. 2011. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Movement Disorders: Official Journal of the Movement Disorder Society 26(1):157–161.CrossRefGoogle ScholarPubMed
Opladen, T, Hoffmann, GF, Blau, N. 2012. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. Journal of Inherited Metabolic Disease 35(6):963–973.CrossRefGoogle ScholarPubMed
Pons, R. 2009. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. Journal of Inherited Metabolic Disease 32(3):321–332.CrossRefGoogle ScholarPubMed
Pons, R, Ford, B, Chiriboga, CA, Clayton, PT, Hinton, V, Hyland, K, et al. 2004. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology 62(7):1058–1065.CrossRefGoogle ScholarPubMed
Pons, R, Syrengelas, D, Youroukos, S, Orfanou, I, Dinopoulos, A, Cormand, B, et al. 2013. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Movement Disorders: Official Journal of the Movement Disorder Society 28(8):1058–1063.CrossRefGoogle ScholarPubMed
Ponzone, A, Blau, N, Guardamagna, O, Ferrero, GB, Dianzani, I, Endres, W. 1990. Progression of 6-pyruvoyl-tetrahydropterin synthase deficiency from a peripheral into a central phenotype. Journal of Inherited Metabolic Disease 13(3):298–300.CrossRefGoogle ScholarPubMed
Ponzone, A, Spada, M, Ferraris, S, Dianzani, I, de Sanctis, L. 2004. Dihydropteridine reductase deficiency in man: from biology to treatment. Medicinal Research Reviews 24(2):127–150.CrossRefGoogle Scholar
Porta, F, Mussa, A, Concolino, D, Spada, M, Ponzone, A. 2009. Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 73(8):633–637.CrossRefGoogle ScholarPubMed
Porta, F, Spada, M, Garelli, D, Mussa, A, Ponzone, A. 2011. Tetrahydrobiopterin and phenylketonuria. The Journal of Pediatrics 158(5):864.CrossRefGoogle ScholarPubMed
Porta, F, Mussa, A, Concolino, D, Spada, M, Ponzone, A. 2012. Dopamine agonists in dihydropteridine reductase deficiency. Molecular Genetics and Metabolism 105(4):582–584.CrossRefGoogle ScholarPubMed
Rajput, AH, Fenton, M, Birdi, S, Macaulay, R. 1997. Is levodopa toxic to human substantia nigra? Movement Disorders: Official Journal of the Movement Disorder Society 12(5):634–638.CrossRefGoogle ScholarPubMed
Regula, JU, Thoden, U, Meinck, HM. 2007. Adult-onset dystonia: atypical manifestation of Segawa disease. Movement Disorders: Official Journal of the Movement Disorder Society 22(9):1335–1337.CrossRefGoogle ScholarPubMed
Ribases, M, Serrano, M, Fernandez-Alvarez, E, Pahisa, S, Ormazabal, A, Garcia-Cazorla, A, et al. 2007. A homozygous tyrosine hydroxylase gene promoter mutation in a patient with dopa-responsive encephalopathy: clinical, biochemical and genetic analysis. Molecular Genetics and Metabolism 92(3):274–277.CrossRefGoogle Scholar
Robinson, R, McCarthy, GT, Bandmann, O, Dobbie, M, Surtees, R, Wood, NW. 1999. GTP cyclohydrolase deficiency: intrafamilial variation in clinical phenotype, including levodopa responsiveness. Journal of Neurology, Neurosurgery, and Psychiatry 66(1):86–89.CrossRefGoogle ScholarPubMed
Roze, E, Vidailhet, M, Blau, N, Moller, LB, Doummar, D, de Villemeur, TB, et al. 2006. Long-term follow-up and adult outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency. Movement Disorders: Official Journal of the Movement Disorder Society 21(2):263–266.CrossRefGoogle ScholarPubMed
Sanford, M, Keating, GM. 2009. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs 69(4):461–476.CrossRefGoogle ScholarPubMed
Sato, H, Uematsu, M, Endo, W, Nakayama, T, Kobayashi, T, Hino-Fukuyo, N, et al. 2014. Early replacement therapy in a first Japanese case with autosomal recessive guanosine triphosphate cyclohydrolase I deficiency with a novel point mutation. Brain & Development 36(3):268–271.CrossRefGoogle Scholar
Saunders-Pullman, R, Blau, N, Hyland, K, Zschocke, J, Nygaard, T, Raymond, D, et al. 2004. Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Molecular Genetics and Metabolism 83(3):207–212.CrossRefGoogle ScholarPubMed
Schiller, A, Wevers, RA, Steenbergen, GC, Blau, N, Jung, HH. 2004. Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 63(8):1524–1526.CrossRefGoogle ScholarPubMed
Schmidt, H, Ullrich, K, Korinthenberg, R, Peters, PE. 1988. Basal ganglion calcification in hyperphenylalaninemia due to deficiency of dihydropteridine reductase. Pediatric Radiology 19(1):54–56.CrossRefGoogle ScholarPubMed
Schuler, A, Blau, N, Ponzone, A. 1995. Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency. European Journal of Pediatrics 154(12):997.CrossRefGoogle ScholarPubMed
Schuler, A, Kalmanchey, R, Barsi, P, Somogyi, CS, Toros, I, Varadi, I, et al. 2000. Deprenyl in the treatment of patients with tetrahydrobiopterin deficiencies. Journal of Inherited Metabolic Disease 23(4):329–332.CrossRefGoogle ScholarPubMed
Sedel, F, Ribeiro, MJ, Remy, P, Blau, N, Saudubray, JM, Agid, Y. 2006. Dihydropteridine reductase deficiency: levodopa’s long-term effectiveness without dyskinesia. Neurology 67(12): 2243–2245.CrossRefGoogle ScholarPubMed
Segawa, M. 2011. Hereditary progressive dystonia with marked diurnal fluctuation. Brain & development 33(3):195–201.CrossRefGoogle ScholarPubMed
Segawa, M, Hosaka, A, Miyagawa, F, Nomura, Y, Imai, H. 1976. Hereditary progressive dystonia with marked diurnal fluctuation. Advances in Neurology 14:215–233.Google ScholarPubMed
Segawa, M, Nomura, Y, Nishiyama, N. 2003. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Annals of Neurology 54(Suppl. 6):S32–S45.CrossRefGoogle Scholar
Sharma, N, Armata, IA, Multhaupt-Buell, TJ, Ozelius, LJ, Xin, W, Sims, KB. 2011. Mutation in 5′ upstream region of GCHI gene causes familial dopa-responsive dystonia. Movement Disorders: Official Journal of the Movement Disorder Society 26(11):2140–2141.CrossRefGoogle ScholarPubMed
Shintaku, H. 2002. Disorders of tetrahydrobiopterin metabolism and their treatment. Current Drug Metabolism 3(2):123–131.CrossRefGoogle ScholarPubMed
Shintaku, H, Ohwada, M. 2013. Long-term follow-up of tetrahydrobiopterin therapy in patients with tetrahydrobiopterin deficiency in Japan. Brain & Development 35(5):406–410.CrossRefGoogle ScholarPubMed
Spada, M, Parrella, T, Ponzone, R, Ferraris, S, Guardamagna, O, Ponzone, A, et al. 1991. Monitoring treatment in tetrahydrobiopterin deficiency. Pteridines. doi: https://doi.org/10.1515/pteridines.1991.3.12.13.CrossRefGoogle Scholar
Stamelou, M, Mencacci, NE, Cordivari, C, Batla, A, Wood, NW, Houlden, H, et al. 2012. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 79(5):435–441.CrossRefGoogle ScholarPubMed
Steinberger, D, Topka, H, Fischer, D, Muller, U. 1999. GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurology 52(4):877–879.CrossRefGoogle Scholar
Steinberger, D, Korinthenberg, R, Topka, H, Berghauser, M, Wedde, R, Muller, U, German Dystonia Study Group. 2000. Dopa-responsive dystonia: mutation analysis of GCH1 and analysis of therapeutic doses of L-dopa. Neurology 55(11):1735–1737.CrossRefGoogle ScholarPubMed
Steinberger, D, Trubenbach, J, Zirn, B, Leube, B, Wildhardt, G, Muller, U. 2007. Utility of MLPA in deletion analysis of GCH1 in dopa-responsive dystonia. Neurogenetics 8(1):51–55.CrossRefGoogle ScholarPubMed
Sun, ZF, Zhang, YH, Guo, JF, Sun, QY, Mei, JP, Zhou, HL, et al. 2014. Genetic diagnosis of two dopa-responsive dystonia families by exome sequencing. PLoS One 9(9):e106388.CrossRefGoogle ScholarPubMed
Surtees, R, Hyland, K. 1990. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. Journal of Neurology, Neurosurgery, and Psychiatry 53(7):569–572.CrossRefGoogle ScholarPubMed
Swoboda, KJ, Hyland, K, Goldstein, DS, Kuban, KC, Arnold, LA, Holmes, CS, et al. 1999. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 53(6):1205–1211.CrossRefGoogle ScholarPubMed
Tachi, N, Takahashi, S, Jo, M, Shinoda, M. 2011. A new mutation of GCH1 in triplets family with dopa-responsive dystonia. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 18(9):1191–1193.CrossRefGoogle ScholarPubMed
Tassin, J, Durr, A, Bonnet, AM, Gil, R, Vidailhet, M, Lucking, CB, et al. 2000. Levodopa-responsive dystonia: GTP cyclohydrolase I or parkin mutations? Brain: A Journal of Neurology 123 (Pt 6):1112–1121.CrossRefGoogle ScholarPubMed
Tay, SK, Poh, KS, Hyland, K, Pang, YW, Ong, HT, Low, PS, et al. 2007. Unusually mild phenotype of AADC deficiency in 2 siblings. Molecular Genetics and Metabolism 91(4):374–378.CrossRefGoogle ScholarPubMed
Theuns, J, Crosiers, D, Debaene, L, Nuytemans, K, Meeus, B, Sleegers, K, et al. 2012. Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystonia. Movement Disorders: Official Journal of the Movement Disorder Society 27(11):1451–1456.CrossRefGoogle ScholarPubMed
Thibert, R, Hyland, K, Chiles, J, Steinberg, S, Eichler, F. 2012. Levodopa response reveals sepiapterin reductase deficiency in a female heterozygote with adrenoleukodystrophy. JIMD Reports 3:79–82.CrossRefGoogle Scholar
Thony, B, Auerbach, G, Blau, N. 2000. Tetrahydrobiopterin biosynthesis, regeneration and functions. The Biochemical Journal 347(Pt 1):1–16.CrossRefGoogle ScholarPubMed
Trender-Gerhard, I, Sweeney, MG, Schwingenschuh, P, Mir, P, Edwards, MJ, Gerhard, A, et al. 2009. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. Journal of Neurology, Neurosurgery, and Psychiatry 80(8):839–845.CrossRefGoogle ScholarPubMed
Uncini, A, De Angelis, MV, Di Fulvio, P, Ragno, M, Annesi, G, Filla, A, et al. 2004. Wide expressivity variation and high but no gender-related penetrance in two dopa-responsive dystonia families with a novel GCH-I mutation. Movement Disorders: Official Journal of the Movement Disorder Society 19(10):1139–1145.CrossRefGoogle ScholarPubMed
Verbeek, MM, Willemsen, MA, Wevers, RA, Lagerwerf, AJ, Abeling, NG, Blau, N, et al. 2008. Two Greek siblings with sepiapterin reductase deficiency. Molecular Genetics and Metabolism 94(4):403–409.CrossRefGoogle ScholarPubMed
Watanabe, T, Matsubara, S, Baba, Y, Tanaka, H, Suzuki, T, Suzuki, M. 2009. Successful management of pregnancy in a patient with Segawa disease: case report and literature review. The Journal of Obstetrics and Gynaecology Research 35(3):562–564.CrossRefGoogle Scholar
Willemsen, MA, Verbeek, MM, Kamsteeg, EJ, de Rijk-van Andel, JF, Aeby, A, Blau, N, et al. 2010. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain: A Journal of Neurology 133(Pt 6):1810–1822.CrossRefGoogle ScholarPubMed
Wu, ZY, Lin, Y, Chen, WJ, Zhao, GX, Xie, H, Murong, SX, et al. 2008. Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families. Clinical Genetics 74(6):513–521.CrossRefGoogle ScholarPubMed
Wu-Chou, YH, Yeh, TH, Wang, CY, Lin, JJ, Huang, CC, Chang, HC, et al. 2010. High frequency of multiexonic deletion of the GCH1 gene in a Taiwanese cohort of dopa-response dystonia. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 153B(4):903–908.Google Scholar
Ye, J, Yang, Y, Yu, W, Zou, H, Jiang, J, Yang, R, et al. 2013. Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study. Journal of Inherited Metabolic Disease 36(5):893–901.CrossRefGoogle ScholarPubMed
Yeung, WL, Wong, VC, Chan, KY, Hui, J, Fung, CW, Yau, E, et al. 2011. Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. Journal of Child Neurology 26(2):179–187.CrossRefGoogle ScholarPubMed
Yosunkaya, E, Karaca, E, Basaran, S, Seven, M, Yuksel, A. 2010. Marked improvement in Segawa syndrome after L-dopa and selegiline treatment. Pediatric Neurology 42(5):348–350.CrossRefGoogle ScholarPubMed
Zirn, B, Steinberger, D, Troidl, C, Brockmann, K, von der Hagen, M, Feiner, C, et al. 2008. Frequency of GCH1 deletions in dopa-responsive dystonia. Journal of Neurology, Neurosurgery, and Psychiatry 79(2):183–186.CrossRefGoogle ScholarPubMed

References

Baschieri, F, Batla, A, Erro, R, Ganos, C, Cordivari, C, Bhatia, KP. 2014. Paroxysmal exercise-induced dystonia due to GLUT1 mutation can be responsive to levodopa: a case report. Journal of Neurology 261(3):615–616.CrossRefGoogle ScholarPubMed
Brockmann, K, Dumitrescu, AM, Best, TT, Hanefeld, F, Refetoff, S. 2005. X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. Journal of Neurology 252(6):663–666.CrossRefGoogle ScholarPubMed
Bruno, MK, Hallett, M, Gwinn-Hardy, K, Sorensen, B, Considine, E, Tucker, S, et al. 2004. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 63(12):2280–2287.CrossRefGoogle ScholarPubMed
Bruno, MK, Lee, HY, Auburger, GW, Friedman, A, Nielsen, JE, Lang, AE, et al. 2007. Genotype–phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology 68(21):1782–1789.CrossRefGoogle ScholarPubMed
Erro, R, Sheerin, UM, Bhatia, KP. 2014a. Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification. Movement Disorders: Official Journal of the Movement Disorder Society 29(9):1108–1116.CrossRefGoogle Scholar
Erro, R, Stamelou, M, Ganos, C, Skorvanek, M, Han, V, Batla, A, et al. 2014b. The clinical syndrome of paroxysmal exercise-induced dystonia: diagnostic outcomes and an algorithm. Movement Disorders: Clinical Practice 1(1):57–61.CrossRefGoogle Scholar
Guimaraes, J, Vale Santos, J. 2000. Paroxysmal dystonia induced by exercise and acetazolamide. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 7(2):237–240.CrossRefGoogle ScholarPubMed
Lee, G, Huang, Y, Washington, JM, Briggs, NW, Zuo, Z. 2005. Carbamazepine enhances the activity of glutamate transporter type 3 via phosphatidylinositol 3-kinase. Epilepsy Research 66(1–3):145–153.CrossRefGoogle ScholarPubMed
Leen, WG, Mewasingh, L, Verbeek, MM, Kamsteeg, EJ, van de Warrenburg, BP, Willemsen, MA. 2013. Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. Movement Disorders: Official Journal of the Movement Disorder Society 28(10):1439–1442.CrossRefGoogle ScholarPubMed
Li, HF, Chen, WJ, Ni, W, Wang, KY, Liu, GL, Wang, N, et al. 2013. PRRT2 mutation correlated with phenotype of paroxysmal kinesigenic dyskinesia and drug response. Neurology 80(16):1534–1535.CrossRefGoogle ScholarPubMed
Li, M, Niu, F, Zhu, X, Wu, X, Shen, N, Peng, X, et al. 2015. PRRT2 mutant leads to dysfunction of glutamate signaling. International Journal of Molecular Sciences 16(5):9134–9151.CrossRefGoogle ScholarPubMed
Mathew, T, Aroor, S, Nadig, R, Sarma, GR. 2012. Lacosamide in paroxysmal kinesigenic dyskinesia. Movement Disorders: Official Journal of the Movement Disorder Society 27(6):801–802.CrossRefGoogle ScholarPubMed
Mencacci, NE, Erro, R, Wiethoff, S, Hersheson, J, Ryten, M, Balint, B, et al. 2015. ADCY5 mutations are another cause of benign hereditary chorea. Neurology 85(1):80–88.CrossRefGoogle ScholarPubMed
Mink, JW. 2015. Treatment of paroxysmal dyskinesias in children. Current Treatment Options in Neurology 17(6):350.CrossRefGoogle ScholarPubMed
Neville, BG, Ninan, M. 2007. The treatment and management of alternating hemiplegia of childhood. Developmental Medicine and Child Neurology 49(10):777–780.CrossRefGoogle ScholarPubMed
Ramm-Pettersen, A, Nakken, KO, Skogseid, IM, Randby, H, Skei, EB, Bindoff, LA, et al. 2013. Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study. Developmental Medicine and Child Neurology 55(5):440–447.CrossRefGoogle ScholarPubMed
Shen, Y, Ge, WP, Li, Y, Hirano, A, Lee, HY, Rohlmann, A, et al. 2015. Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis. Proceedings of the National Academy of Sciences of the United States of America 112(10):2935–2941.CrossRefGoogle ScholarPubMed
Suls, A, Dedeken, P, Goffin, K, Van Esch, H, Dupont, P, Cassiman, D, et al. 2008. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain: A Journal of Neurology 131(Pt 7):1831–1844.CrossRefGoogle ScholarPubMed
Verge, CF, Konrad, D, Cohen, M, Di Cosmo, C, Dumitrescu, AM, Marcinkowski, T, et al. 2012. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. The Journal of Clinical Endocrinology and Metabolism 97(12):4515–4523.CrossRefGoogle ScholarPubMed
Yang, Y, Su, Y, Guo, Y, Ding, Y, Xu, S, Jiang, Y, et al. 2012. Oxcarbazepine versus carbamazepine in the treatment of paroxysmal kinesigenic dyskinesia. The International Journal of Neuroscience 122(12):719–722.CrossRefGoogle ScholarPubMed
Yokoyama, CT, Myers, SJ, Fu, J, Mockus, SM, Scheuer, T, Catterall, WA. 2005. Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site. Molecular and Cellular Neurosciences 28(1):1–17.CrossRefGoogle ScholarPubMed